GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Perindopril erbumine (Aceon)

Read renal action and limits

Aceon

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Aceon - product and source limitations

This is the erbumine salt. Check blood pressure, renal function and potassium during treatment.

Before applying: Verify the current prescribing information for this presentation.

Also check: Aceon - product and source limitations

Official source

Aceon - labeled renal guidance

Renal action and limits

Perindopril erbumine (Aceon), adult oral tablets
Creatinine clearance (CrCl), mL/min; use the product-specific calculation

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Action or finding
Below CrCl 30 mL/min, use is not recommended. For less severe renal impairment, start at 2 mg/day and limit the total to 8 mg/day.
Limits and monitoring
This is the erbumine salt. Check blood pressure, renal function and potassium during treatment.
Before use
Verify the current prescribing information for this presentation.

DailyMed SPL version 3, effective 2013-03-11; posted Mar 20, 2013 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source GlobalRPh RX passage All evidence
Product / population
Perindopril erbumine (Aceon), adult oral tablets
Renal measure
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source revision
DailyMed SPL version 3, effective 2013-03-11; posted Mar 20, 2013
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Renal guidance: Dosage in renal impairment

Below CrCl 30 mL/min, use is not recommended. For less severe renal impairment, start at 2 mg/day and limit the total to 8 mg/day. This is the erbumine salt. Check blood pressure, renal function and potassium during treatment.

Source revision: DailyMed SPL version 3, effective 2013-03-11; posted Mar 20, 2013 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97a9e8bf-91ed-4256-97d4-f9504bb01373

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Aceon - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Perindopril erbumine (Aceon), adult oral tablets

Renal method: Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Retrieved: 2026-11-07

GlobalRPh RX List

Aceon - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Perindopril erbumine (Aceon), adult oral tablets

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Aceon - product and source limitations

This is the erbumine salt. Check blood pressure, renal function and potassium during treatment.

How to use this: Verify the current prescribing information for this presentation.

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/medications-with-general-renal-dosing-statements/

GlobalRPh general renal statement

Dose Adjustment in Renal Impairment and Dialysis: Perindoprilat elimination is decreased in renally impaired patients. ACEON is not recommended in patients with creatinine clearance <30 mL/min. For patients with lesser degrees of impairment, the initial dosage should be 2 mg/day and dosage should not exceed 8 mg/day. During dialysis, perindopril is removed with the same clearance as in patients with normal renal function.

GRPH-general-perindopril-01 · Source section: GlobalRPh general renal statementRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Aceon - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Perindopril erbumine (Aceon), adult oral tablets

Renal method: Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source date: DailyMed SPL version 3, effective 2013-03-11; posted Mar 20, 2013
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Dosage in renal impairment

Below CrCl 30 mL/min, use is not recommended. For less severe renal impairment, start at 2 mg/day and limit the total to 8 mg/day. This is the erbumine salt. Check blood pressure, renal function and potassium during treatment.

RDM73-aceon-official-1 · Source locator: Renal guidance: Dosage in renal impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97a9e8bf-91ed-4256-97d4-f9504bb01373
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source date/version
DailyMed SPL version 3, effective 2013-03-11; posted Mar 20, 2013
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
88a5d497e7020f03fa24f7e0753d0fdeb46238552fac18b324b4e23be2ea3fd6
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Aceon - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Perindopril erbumine (Aceon), adult oral tablets

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror gives an initial dose and daily maximum for impaired patients above its exclusion threshold.

RDM73-aceon-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/aceon-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
7fb8d42e6c9310930c89b89db39729b47a0c7fb1a0ab75ea4920d1d8b67d760f

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/medications-with-general-renal-dosing-statements/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph general · Numbered general entry 20
Local text SHA-256
c7674251972f10bef085dc20472237511780b26a9bfc6a86a84073ef58941b93
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top